plato-a-magriotis
Plato A Magriotis, Ph D
Associate Professor

Laboratory of Pharmaceutical Chemistry
Department of Pharmacy
School of Health Sciences
University of Patras, Rio, Patras, Greece
Phone: +302610-962311
E-mail: pmagriotis@upatras.gr

Education

1983-1986 Postdoctoral Fellow ; Harvard University, USA USA
1983 Ph.D. in Chemical Biology; SUNY at Stony Brook, USA USA
1978 B.Sc. in Chemistry, University of Athens, Greece  Greece 

Biography

Since 2006, Plato A. Magriotis, Ph.D., is an Associate Professor of Medicinal Chemistry in the Department of Pharmacy at the University of Patras in Greece and a Research Affiliate with the Department of Chemistry at New York University. Magriotis received his Ph.D. in Chemical Biology with Professor Francis Johnson at Stony Brook University in 1983 and did Postdoctoral work at Harvard University with Nobel Laureate Professor E. J. Corey. His career started at West Virginia University and continued at Merck & Co. as well as New York University in the U.S., prior to his return to Greece. Magriotis’ research program focuses on the development of new methodology for the synthesis of relevant pharmacophores applied in drug discovery.


Research Interest

  • Synthesis of biologically and pharmacologically relevant molecules such as a- and b-amino acids, b-lactams, piperidines, and piperazines.
  • Total Synthesis of antitumor, antibiotic Natural Products (Cyclostreptin-(-)-FR182877, Ecteinascidin 743, Saframycin A, and Abyssomicin C).
  • New Synthetic Methodology including novel routes to b-lactams, piperazines and tetrasubstituted olefins (Tamoxifen analogs).
  • Importance of Catalytic Asymmetric Synthesis of Saturated N-Heterocucles in Chemical Biology and Pharmaceutical Chemistry

The important requirement for approval of a new drug, in case it happens to be chiral, that both enantiomers of the drug be studied in detail, have focused the attention of synthetic organic and medicinal chemists on the development of new methods for catalytic asymmetric synthesis especially of relevant saturated N-heterocycles. Despite the success of chirally modified transition-metal catalysts in asymmetric synthesis, in the form of the Nobel Prize in Chemistry in 2001, the field of asymmetric organic synthesis has since then been dominated by organocatalysts due to their ability to catalyze a variety of fundamentally important transformations in medicinal chemistry and therefore chemical biology. One example is the Staudinger synthesis of β-lactams representing one class of saturated N-heterocycles and continuing to provide unique opportunities for the discovery of new derivatives with novel pharmacological profiles. Specifically, β-lactams have recently been found to have potential as the basis for treatments  for neurological disorders including amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Although significant progress has been made in asymmetric organocatalytic Staudinger synthesis of β-lactams since the inaugural and pioneering investigations by Lectka and coworkers around the turn of the century, the same did not hold true regarding the development of a novel Gilman-Speeter process for the catalytic enantioselective synthesis of β-lactams. Efforts directed at this latter goal are ongoing in this Laboratory.

On the other hand, the piperazine ring, besides defining a major class of saturated N-heterocycles, has been classified as a priviledged structure in Medicinal Chemistry since it is more than frequently found in biologically active compounds including several marketed blockbuster drugs such as Glivec (Imatinib) and Viagra (Sildenafil). Actually, an analysis of all U.S. FDA approved small molecule drugs found that 21% contained saturated 6-membered N-heterocycles with an additional heteroatom (N, piperazines; O, morpholines; S, thiomorpholines). Indeed, 13 of the 200 best-selling small molecule drugs in 2012 contain a piperazine ring.  In the vast majority of these molecules, however, the piperazine ring is not substituted on any of its carbon atoms. Specifically, analysis of the piperazine substitution pattern reveals a luck of structural diversity, with almost every single drug in this category (83%) containing a substituent at both the N1- and N4-positions compared to only a few drugs having a substituent at any other position (C2, C3, C5, and C6).4 Significant chemical space that is closely related to that known to be biologically relevant, therefore, remains unexplored. In order to explore this chemical space, an efficient and enantioselective synthesis of C-substituted piperazines must be designed and developed. Efforts toward the implementation of this particular target are also ongoing in this Laboratory. Since piperazine derivatives have been reported to elicit a broad spectrum of pharmacological activities including antidepressant, anticancer, antihelmentic, antibacterial, antifungal, antimycobacterial, antimalarial, antituberculant, anticonvulsant, and anti-AIDS; one can easily comprehend that the sky will be the limit, as far as novel drug development is concerned, once this catalytic enantioselective process will be fully developed.


Scientific Activities

Honors And Awards
  • Peer Reviewer Status in several Scientific Journals ( Tetrahedron Letters, Journal of Organic Chemistry, Journal of the American Chemical Society, Organic Letters, Synthesis Letters, Angewandte, Chemie International Edition, Tetrahedron: Asymmetry)
  • Award for Excellence in Teaching, 1982, SUNY at Stony Brook, Department of Chemistry.
  • Μerck Fellowship, 8/9/95-9/9/96, Harvard University, Department of Chemistry and Chemical Biology (Advisor: Professor Elias J. Corey)
  • ACS-PRF #20811-G1, “Asymmetric Synthesis via Binaphthyl Derived Organo-metallic Reagents.” 9/1/88-8/31/90, $18,000.
  • NSF #CHE-8913626, “Purchase of a Gas Chromatography/Mass Spectrometer System.” 9/1/89-8/31/90, $40,819.
  • American Cancer Society #IN-181, “Studies on the Synthesis of the Power-ful Cell Growth Inhibitor Cephalostatin I.” 8/1/89-7/31/91, $7,500.
  • NSF #CHE-901242, “Group Travel for U.S. Participants in 8th International IUPAC Conference on Organic Synthesis; Helsinki, Finland, July 23-27, 1990.”; $1,500.
  • American Cancer Society #CH-496, “A Unified Strategy for the Synthesis of Enediyne Antitumor Antibiotics.” 7/1/90-6/30/92, $160,000.
  • NSF #CHE-9120098, “Purchase of an Automated Single-Crystal X-Ray Diffractometer.” 12/1/91-5/31/93, $108,000.
  • SmithKline Beecham Pharmaceuticals, “The Enediyne Route to the Synthesis of Taxol and Related Compounds.” 6/1/92, $2,000.
  • Stavros Niarchos Foundation, “Purchase of  Chiral HPLC Instrumentation” October 2017. € 40,000.

Publications

  1. Steroids I.  Alkylation of -Ketoesters via their Cu(II) Enolates in Aqueous Media. Application to the Synthesis of C-18 Functionalized Steroids via the Torgov Approach.” Magriotis, P. A.; Murray, W. V.; Johnson, F. Tetrahedron Lett. 1982, 23, 1993-1996.
  2. “Novel Synthetic Approaches to Racemic and Optically Active Steroids.”  Magriotis, P. A. Ph.D. Dissertation, SUNY at Stony Brook, 1983.  Diss. Abst. Int. B 1984, 44, 3084 (Order No. 8401443).
  3. Steroids III.  A New Synthetic Approach to Optically Active Steroids.  Total Synthesis of (+)-18-Hydroxyestrone.”  Magriotis, P. A.; Johnson, F. J. Org. Chem. 1984, 49, 1460-1461.
  4. “A New Cr(VI) Reagent for the Catalytic Oxidation of Secondary Alcohols to Ketones.” Corey, E. J.; Barrette, E.-P.; Magriotis, P. A. Tetrahedron Lett. 1985, 26, 5855-5858.
  5. Halocarbon Chemistry II.  Use of the 1,1-Difluoro-2,2-dichloroethyl Group for Phenol Protection.  Regulation of Ionization During the Torgov Steroid Synthesis.”  Will, S. A.; Magriotis, P. A.; Marinelli, E. R.; Dolan, J.; Johnson, F. J. Org. Chem. 1985, 50, 5432-5433.
  6. “Total Synthesis and Absolute Configuration of 7,20-Diisocyanoadociane.”  Corey, E. J.;  Magriotis, P. A. J. Am. Chem. Soc. 1987, 109, 287-289.
  7. “Stereoselective Construction and Synthetic Applications of Phenylthio Substituted Iodoolefins.”  Magriotis, P. A.; Doyle, T. J.; Kim, K. D. Tetrahedron Lett. 1990, 31, 2541-2544.
  8. “A New Stereoselective Synthesis of (Z)-Vinylsilane Allylic Alcohols.”  Kim, K. D.; Magriotis, P. A. Tetrahedron Lett. 1990, 31, 6137-6140.
  9. “A Highly Selective Synthesis of Versatile (E)-1-Phenylthio Vinylstannanes.”  Magriotis, P. A.; Brown, J. T.; Scott, M. E. Tetrahedron Lett. 1991, 32, 5047-5050.
  10. “A Novel Approach to the Synthesis of Enediynes.”  Magriotis, P. A.; Scott, M. E.; Kim, K. D. Tetrahedron Lett. 1991, 32, 6085-6088.
  11. “Synthesis of Phenylthioacetylene.”  Magriotis, P. A.; Brown, J. T. Org. Synth. 1993, 72, 252-264.
  12. “Novel Generation of Alkynyl Ketenes: Efficient Synthesis of -Alkynyl Lactones.” Magriotis, P. A.; Scott, M. E.; Vourloumis, D.; Tarli, A. Tetrahedron Lett. 1993, 34, 2071-2074.
  13. “Ireland-Claisen Rearrangement of Enediyne Lactones: Tandem Claisen-Bergman Strategy for Tetrahydronaphthalene Synthesis.”  Magriotis, P. A.; Kim, K. D. J. Am. Chem. Soc. 1993, 115, 2972-2973.
  14. t-Butoxyacetylene.”  Magriotis, P. A. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A. Ed.; John Wiley & Sons: Chichester, 1995; Vol 2, 826-827.
  15. “Methylthioacetylene.”  Magriotis, P. A. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A. Ed.; John Wiley & Sons: Chichester, 1995; Vol 5, 3586-3587.
  16. “Phenylthioacetylene.” Magriotis, P. A. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A. Ed.; John Wiley & Sons: Chichester, 1995; Vol 6,  4067-4068.
  17. “Cobalt-Assisted Claisen Rearrangement of Enediyne Lactones at Ambient Temperature. Studies toward a Synthetic Application of the Myers Cycloaromatization.” Vourloumis, D.; Kim. K. D.; Petersen, J. L.; Magriotis, P. A. J. Org. Chem. 1996, 61, 4848-4852.
  18. “Direct Catalytic Enantioselective Reduction of Achiral -Ynones.  Strong Remote Steric Effects Across the C-C Triple Bond.”  Helal, C. J.; Magriotis, P. A.; Corey, E. J. J. Am. Chem. Soc. 1996, 118, 10938-10939.
  19. Co-inventor on the following U.S. patent application: “Preparation of Substituted -Alanine Derivatives as Cell Adhesion Inhibitors.”  Durette, P. L.;Hagmann, W. K.; Kopka, I. E.; MacCoss, M.; Mills, S. G.;Mumford, R. A.; Magriotis, P. A. (PCT Application WO 99 26,921) Chem. Abstr. 1999, 131, 5529n.
  20. “Recent Progress in the Enantioselective Synthesis of -Lactams: Development of the first Catalytic Approaches”  Magriotis, P. A. Angew. Chem., Int. Ed. Engl. 2001, 40, 4377-4379.
  21. “Neues uber die enantioselektive Synthese von -Lactamen: Entwicklung der ersten Katalytischen Ansatze”  Magriotis, P. A. Angew. Chem. 2001, 113, 4507.
  22. “The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists”  Hagmann, W. K.; Durette, P. L.; Lanza, T.; Kevin, N. J.; de Laszlo, S. E.; Kopka, I. E.; Young, D.; Magriotis, P. A.; Li, B.; Lin, L. S.; Yang, G.; Kamenecka, T.; Chang, L. L.; Wilson, J.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.; Egger, L. A.; Kidambi, U.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Tong, S.; Fenyk-Melody, J.; Owens, K.; Levorse, D.; Kim, P.; Schmidt, J. A.; Mumford, R. A. Bioorg. Med. Chem. Lett. 2001, 11, 2709-2713.
  23. “N-Tetrahydrofuroyl-(L)-Phenylalanine Derivatives As Potent VLA-4 Antagonists”  Yang, G. X.; Chang, L. L.; Truong, Q.; Doherty, G. A.; Magriotis, P. A.; de Laszlo, S. E.; Li, B.; MacCoss, M.;Kidambi, U.; Egger, L. A.; McCauley, E.; Van Riper, G.; Mumford, R. A.; Schmidt, J. A.; Hagmann, W. K. Bioorg. Med. Chem. Lett. 2002, 12, 1497-1500.
  24. “Substituted N-(3,5-Dichlorobezenesulfonyl)-L-Prolyl-Phenylalanine Analogues as Potent VLA-4 Antagonists”  Kopka, I. E.; Young, D.; Lin, L.; Mumford, R. A.; Magriotis, P. A.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.; Egger, L.; Kidambi, U.; Schmidt, J. A.; Lyons, K.; Stearns, R.; Vincent, S.; Colletti, A.; Wang, Z.; Tong, S.; Wang, J.; Zheng, S.; Owens, K.; Levorse, D.; Hagmann, W. K. Bioorg. Med. Chem. Lett. 2002, 12, 637-640.
  25. “Substituted -Amino Biaryl Propionic Acids as Potent VLA-4 Antagonists”  Kopka, I. E.; Lin, L. S.;Mumford, R. A.; Lanza, T.; Magriotis, P. A.; Young, D.; deLaszlo, S. E.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.;Lyons, K.; Vincent, S.; Egger, L. A.; Stearns, R.; Colletti, A.; Tong, S.; Owens, K.; Levorse, D.; Schmidt, J. A.; Hagmann, W. K. Bioorg. Med. Chem. Lett. 2002, 12, 2415-2418.
  26. “The Discovery of Acylated -Amino Acids as Potent and Orally Bioavailable VLA-4 Antagonists”  Lin, L. S.; Kopka, I. E.; Mumford, R. A.; Magriotis, P. A.; Lanza, T.; Durette, P. L.; Kamenecka, T.; Young, D. N.; deLaszlo, S. E.; McCauley, E.; Van Riper, G.; Kidambi, U.; Egger, L. A.; Tong, X.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Fenyk-Melody, J.; Schmidt, J. A.; MacCoss, M.; Hagmann, W. K. Bioorg. Med. Chem. Lett. 2002, 12, 611-614.
  27. “Novel Applications of the Schöllkopf Chiral Auxiliary: A New and Efficient Enantioselective Synthesis of -Lactams Possessing a C-4 Quaternary Stereocenter” Vassiliou, S.; Dimitropoulos, C.; Magriotis, P. A. Synlett 2003, 2398-2400.
  28. “A New Method for the Functionalization of [60] Fullerene: An Unusual 1,3-Dipolar Cycloaddition Leadind to a C60 Housane Derivative” Zhou, Z.; Magriotis, P. A. Org. Lett. 2005, 7, 5849-5851.
  29. “Improved Schöllkopf Construction of Quaternary -Amino Acids: Efficient Enantioselective Synthesis of Integrin LFA-1 Antagonist BIRT-377” Vassiliou, S.; Magriotis, P. A. Tetrahedron: Asymmetry 2006, 17, 1754-1757.
  30. “Efficient Enantioselective Synthesis of Orthogonally Protected (R)--Alkylserines Compatible with the Solid Phase Peptide Synthesis” Tetrahedron Letters 2006, 47, 7339-7341.
  31. “Synthesis of the Metabotropic Receptor Ligand (2S)-a-(Hydroxyymethyl)- glutamic acid and its Fmoc Protected Derivatives” Yiotakis A.; Magriotis, P. A.; Vassiliou, S. Tetrahedron: Asymmetry 2007, 18, 873-877.
  32. "Importance of Mechanistic Drug Metabolism Studies in Support of Drug Discovery: A Case Study with a N-Sulfonylated dipeptide VLA-4 Antagonist in Rats" Tang, W.; Stearns, R. A.; Chen, Q.; Bleasby, K.; Teffera, Y.; Colletti, A.; Hafey, M.; Evers, R.; Dean, D. C.; Μagriotis, P. A.; Lanza, T.J.; Lin, L.S.; Hagmann, W.K.; Baillie, T.A. Xenobiotica 2008, 38, 223-237.
  33. “Progress in Asymmetric Organocatalytic Synthesis of β-Lactams” Magriotis, P. A. Eur. J. Org. Chem. 2014, 2647-2657.
  34. “Synthetic Approaches to the Stereochemically Complex Antitumor Drug Ecteinascidin-743: A Marine Natural Product by the Name Yondelis® or Trabectidin” Chapter in a book dedicated to the great pioneer of Stereochemistry Ernest Eliel.
Presentations
  1. “Stereochemical Problems Associated with the Total Synthesis of 7,20-Diisocyanoadociane.”  Department of Chemistry, Michigan State University (Colloquium); December, 1987.
  2. “Stereoselective Synthesis of -Methyl Cyclohexylamine Derivatives.”  Magriotis, P. A.; Corey, E. J.; Ghosh, A. K.; Ishiguro, M. American Chemical Society, 20th Central Regional Meeting (Oral Presentation); Morgantown, WV; June, 1988.
  3. “Design and Synthesis of Mechanism-Based Enzyme Inhibitors.”  Department of Chemistry, Shippensburg University (Recruiting): April, 1989.
  4. “Stereoselective Synthesis and Synthetic Applications of Phenylthio Substituted Iodoolefins.”  Magriotis, P. A.; Doyle, T. J.; Kim, K. D. American Chemical Society, 199th National Meeting (Oral Presentation); Boston, MA; April 1990.
  5. “Studies on the Synthesis of Enediyne Antitumor Antibiotics.”  Magriotis, P. A.; Kim, K. D.; Scott, M. E. 8th International IUPAC Conference on Organic Synthesis (Oral Presentation); Helsinki, Finland; July, 1990.
  6. “A New Stereoselective Synthesis of (Z)-Vinylsilane Allylic Alcohols.”  Kim, K. D.; Magriotis, P. A. American Chemical Society, 200th National Meeting (Poster); Washington, D.C.; August, 1990.
  7. “Studies on the Synthesis of Enediyne Antitumor Antibiotics.”  Department of Chemistry, Kent State University (Colloquium); November, 1990.
  8. “Synthetic Studies on the Calicheamicin/Esperamicin and Neocarzinostatin Antibiotics.” School of Pharmacy, West Virginia University (Colloquium); February, 1991.
  9. “A Claisen Rearrangement Approach to the Synthesis of Enediyne Antibiotics.” Department of Chemistry, The University of Akron (Colloquium); February, 1991.
  10. “Development of Synthetic Methods toward the Enediyne Antitumor Antibiotics.” Department of Chemistry, SUNY at Stony Brook (Colloquium); March 1991.
  11. “A Novel Approach to the Synthesis of Enediynes.”  Magriotis, P. A.; Scott, M. E. American Chemical Society, 201st National Meeting (Poster); Atlanta, GA; April 1991.
  12. “A Highly Selective Synthesis of Versatile (E)-1-Phenylthio Vinylstannanes.”  Magriotis, P. A.; Brown, J. T.; Kim, K. D. American Chemical Society, 32nd National Organic Chemistry Symposium (Poster); Minneapolis, MN; June 1991.
  13. “Application of Novel Organic Reactions and Processes to the Synthesis of Enediyne Models related to Calicheamicin/Esperamicin Antibiotics.”  Gordon Conference on Organic Reactions and Processes (Poster); New Hampton, NH; July 1991.
  14. “Progress on the Claisen Rearrangement Approach to the Synthesis of Enediyne Antibiotics” Gordon Conference on Natural Products (Poster); New Hampton, NH; July 1991.
  15. “An Organometallic Approach to the Synthesis of Enynes and Enediynes.”  Magriotis, P. A; Scott, M. E.; Kim, K. D. 6th IUPAC Symposium on Organometallic Chemistry directed towards Organic Synthesis (Poster); Utrecht, The Netherlands; August 1991.
  16. “Progress on the Claisen Rearrangement Approach to the Synthesis of Enediyne Antibiotics.”  Department of Chemistry, Virginia Polytechnic Institute and State University (Colloquium); November 1991.
  17. “The Claisen Rearrangement Approaches to the Synthesis of Enediyne Anticancer Antibiotics.”  Department of Chemistry, The Scripps Research Institute (Colloquium); April 1992.
  18. “The Claisen Rearrangement Approach to the Synthesis of Calicheamicin/Esperamicin and Neocarzinostatin Precursors and Analogues.”  Magriotis, P. A.; Kim, K. D.; Scott, M. E. American Chemical Society, 201st National Meeting (Oral Presentation); San Francisco, CA; April 1992.
  19. “The Claisen Rearrangement Approach to Enediyne Antitumor Antibiotics.” Department of Chemistry, California Institute of Technology (Colloquium); April 1992.
  20. “The Claisen Rearrangement Strategy for the Stereocontrolled Synthesis of Neocarzinostatin Chromophore Aglycon.”  Magriotis, P. A.; Scott, M. E. 9th International IUPAC Conference on Organic Synthesis (Poster); Montreal, Canada; June, 1992.
  21. “Ireland-Claisen Rearrangement of Enediyne Lactones: Tandem Claisen-Bergman Strategy for Tetrahydronaphthalene Synthesis.”  Gordon Conference on Organic Reactions and Processes (Oral Presentation); New Hampton, NH; July 1992.
  22. “Ireland-Claisen Rearrangement of Enediyne Lactones: Tandem Claisen-Bergman Strategy for Stereoselective Tetrahydronaphthalene Synthesis.”  Gordon Conference on Natural Products (Oral Presentation); New Hampton, NH; July 1992.
  23. “Sigmatropic Rearrangements of 3-Ene-1,5-diyne Lactones: New Stereoselective Synthesis of Highly Substituted Tetrahydronaphthalene Derivatives via Tandem Ireland-Claisen/Bergman Rearrangements.”  Magriotis, P. A.; Kim, K. D. American Chemical Society, 204th National Meeting (Oral Presentation); Washington, DC; August 1992.
  24. “Studies toward the Synthesis of Antitumor Antimitotic Agents Taxol and Podophyllotoxin.”  5th Symposium on the Latest Trends in Organic Synthesis (Invited Lecture); Blacksburg, VA; October 1992.
  25. “Studies toward the Synthesis of Antitumor Antimitotic Agents Taxol and Podophyllotoxin.”  Department of Chemistry, University of Pittsburgh (Colloquium); March 1993.
  26. “Novel Generation of Conjugated Alkynyl Ketenes: Efficient Synthesis of -Alkynyl Lactones.”  Magriotis, P. A.; Vourloumis, D.; Scott, M. E.; Tarli, A. American Chemical Society, 205th National Meeting (Sci-Mix Poster*); Denver, CO; April 1993.
  27. *Selected among the 10 best scientific works of the Organic Division of ACS and presented at the SCIMIX of the same Meeting.
  28. “A New and General Synthesis of (Z)-Enol Ethers.”  Magriotis, P. A.; Lu, Y.-D.; Hu, J.; Kim, K. D. American Chemical Society, 33rd National Organic Chemistry Symposium (Poster); Bozeman, MT; June 1993.
  29. “Claisen Rearrangement of Enediyne Substrates: Studies toward the Synthesis of NCS Chromophore and Tandem Claisen-Bergman Strategy for Stereocontrolled Tetrahydronaphthalene Construction.”  Magriotis, P. A.; Kim, K. D.; Tarli, A.; Vourloumis, D.; Hu, J. American Chemical Society, 28th Midwest Regional Meeting (Invited Lecture, Symposium on Recent Advances in the Chemistry of Enediynes); Columbia, MO; November 1993.
  30. “Studies toward the Synthetic Application of the Bergman and Myers Reactions” Department of Chemistry, Brown Universitry (Colloquium); February 1996.
  31. “Discovery of Tetrahydrofuroyl-1-phenylalanine Derivatives as Potent VLA-4 Antagonists”  Yang, G. X.; Doherty, G. A.; Chang, L.L.; deLaszlo, S. E.; Li B.; Magriotis, P. A.; Truong, Q.; Hagmann, W. K.; MacCoss, M.; Tong, X.; Kidambi, U.; Egger, L.; MacCauley, E.; Van Riper, G.; Schmidt, J. A.; Mumford, R. A. American Chemical Society, 222nd National Meeting (Poster); Chicago, IL; August 2001.
  32. “Studies toward the Synthetic Application of the Bergman and Myers Reactions” Department of Chemistry, New York University (Colloquium); February 2002.
  33. “Orally Active Conformationally Constrained Small Molecule VLA-4 Antagonists”  Chang, L. L.; Truong; Q.; Doss, G.; Lin, L.; Magriotis, P. A.; MacCoss, M.; Lyons, K.; MacCauley, E.; Mumford, R. A.; Van Riper, G.;Vincent, S.; Schmidt, J. A.; Hagmann, W. K. American Chemical Society, 224th National Meeting (Poster); Boston, MA; August 2002.”
  34. “Novel Applications of the Schöllkopf Chiral Auxiliary: A New and Efficient Enantioselective Synthesis of -Lactams Possessing a C-4 Quaternary Stereocenter” Dimitropoulos, C.; Vassiliou, S.; Magriotis, P. A. American Chemical Society, 226th National Meeting (Oral Presentation), New York, NY, September 2003.
  35. “Asymmetric Synthesis of -Amino Acids and -Lactams: From Auxiliary-Driven to Catalytic Enantioselective Methodology” Department of Chemistry, State University of New York at Stony Brook (Invited Lecture), July 2005.
  36. “Synthesis of Small Molecules as Integrin Antagonists. Asymmetric Synthesis of -Amino Acids and -Lactams: From Auxiliary-Driven to Catalytic Enantioselective Methodology.”Center for Neurologic Diseases, Harvard Medical School and Brigham and Women’s Hospital; (Special Seminar), Boston, MA, August 2005.
  37. “Synthesis of Small Molecules as Integrin Antagonists. Asymmetric Synthesis of -Amino Acids and -Lactams.” Department of Pharmacy, School of Health Sciences, University of Patras (Special Seminar), Rio, Patras, Greece, November 2005.
  38. “Synthesis of Small Molecules as Integrin Antagonists. Asymmetric Synthesis of -Amino Acids and -Lactams.”           Institute of Physical Chemistry (Chemical Biology), NCSR <<DEMOCRITOS>> (Invited Seminar), Athens, Greece, September 2006.
  39. “Efficient Enantioselective Synthesis of Orthogonally Protected Metabotropic Receptor Ligand (2S)--(Hydroxymethyl)-glutamic acid and (R)--Alkylserines Compatible with Solid-Phase Peptide Synthesis and Useful in Peptidomimetic Drug Design” Vassiliou, S.; Yiotakis, A.; Magriotis, P. A. 2nd Bioscience Conference (Poster Presentation), University of Patras; Rio, Patras, Greece, April 2007.
  40. “S-Oxide Activated Mannich Reactions in Medicinal Chemistry: Enantioselective Synthesis of Substituted -Lactams” Psarra, V.; Magriotis, P. A. 3rd Hellenic Symposium on Organic Synthesis. From Chemistry to Biology, Medicine and Materials Science (Invited Short Lecture), University of Athens, Athens, Greece, October 2009.
  41. “Studies toward the Total Synthesis of Ecteinascidin 743: New Synthetic Technologies in Medicinal Chemistry” Magriotis, P. A.; (Invited Lecture) Department of Pharmacy, University of Bari, Italy, December 2009.
  42. “Studies toward the Total Synthesis of Ecteinascidin 743: New Synthetic Technologies in Medicinal Chemistry” Magriotis, P. A.; Psarra, V. (Poster Presentation) 14th Hellenic Symposium on Medicinal Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece, April 2010.
  43. “Studies toward the Total Synthesis of Ecteinascidin 743: New Synthetic Technologies in Medicinal Chemistry” Magriotis, P. A.; Psarra, V. (Invited Lecture) 11th Conference on Medicinal Chemistry, University of Patras, Rio, Greece, April 2010.
  44. “Studies toward the Total Synthesis of Ecteinascidin 743: New Synthetic Technologies in Medicinal Chemistry” Magriotis, P. A. (Invited Lecture) Francis Johnson Symposium, Departments of Pharmacological Sciences and Chemistry, Stony Brook University, Stony Brook, USA, October 2010.
  45. “Studies toward the Total Synthesis of Ecteinascidin 743: Discovery of a New β-Lactam Synthesis” Magriotis, P. A.; Lerogianni, M.; Panagiotou, M.; Nikolopoulos, P.. (Poster Presentation) 1st Conference of Pharmaceutical Sciences, University of Athens, Athens, Greece, April 2012.
  46. “Studies toward a Novel Total Synthesis of Ecteinascidin 743: Discovery of a New and Practical Synthesis of β-Lactams” Magriotis, P. A.; Panagiotou, M.; Nikolopoulos, P.. (Poster Presentation) 22nd International Symposium on Medicinal Chemistry, Estrel Convention Center, Berlin, Germany, September 2012.
  47. “Studies toward the Total Synthesis of the Anticancer Drug and Marine Natural Product Yondelis”  Magriotis, P. A. (Invited Lecture) , 2nd Conference of Pharmaceutical Sciences, University of Patras, Rio, Greece, October 2014.
  48. “Synthesis of an Optimized Inhibitor of the Arp2/3 Complex which is a Key Regulator of the Actin Cytoskeleton” Magriotis, P. A.; Hetrick, B.; Nolen, B.; Patargias, G.; Panagiotoy, M.; Cournia, Z. (Poster Presentation) 14th Hellenic Symposium on Medicinal Chemistry, University of Patras, Rio, Greece, January 2015.
  49. “Drug Development from Marine Natural Products: The Case of the Anticancer Drug Yondelis” Magriotis, P. A. (Invited Lecture) 1st Conference of Applied Pharmacy, Met Hotel, Thessaloniki, Greece, April 2015.
  50. “Design and Development of Novel methodology for the Synthesis of Substituted Piperazines Inspired by the Mechanism of Action of the Antitumor Drug and Marine Natural Product Yondelis” Magriotis, P. A. (invited Lectuire) , 3rd    Conference of Pharmaceutical Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece, February, 2017.
  51. “Asymmetric Organocatalytic Gilman-Speeter Synthesis of β-Lactams” Magriotis, P. A. Karakoula, A.; Moraiti, K.; Mourtzaki, A.; Naeratos, S. (Poster Presentation) 17th Hellenic Symposium on Medicinal Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece, June, 2017.

Medicinal Chemistry and Drug Design Flyer